Raymond James Initiates Coverage On Monopar Therapeutics with Strong Buy Rating, Announces Price Target of $80
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Raymond James analyst Chris Raymond initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy rating and announces Price Target of $80.
Raymond James analyst Chris Raymond initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy rating and announces Price Target of $80.